Evidence map›Paper›PMID 37448562›Full record

ArticleiScience2023

Polycomb repressive complex 2 binds and stabilizes NANOG to suppress differentiation-related genes to promote self-renewal.

Da-Wei Yeh, Cheng Liu, Juan Carlos Hernandez, Stanley M Tahara, Hidekazu Tsukamoto, Keigo Machida

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Da-Wei YehDepartments of Molecular Microbiology and Immunology, University of Southern California, Los Angeles, CA 90033, USA.
Cheng LiuDepartments of Molecular Microbiology and Immunology, University of Southern California, Los Angeles, CA 90033, USA.
Juan Carlos HernandezDepartments of Molecular Microbiology and Immunology, University of Southern California, Los Angeles, CA 90033, USA.
Stanley M TaharaDepartments of Molecular Microbiology and Immunology, University of Southern California, Los Angeles, CA 90033, USA.
Hidekazu TsukamotoDepartment of Pathology; University of Southern California, Los Angeles, CA 90033, USA.
Keigo MachidaDepartments of Molecular Microbiology and Immunology, University of Southern California, Los Angeles, CA 90033, USA.
University of Southern California · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
The Southernearch Center for ALPD and CirrhosisP50AA011999 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ANNA S. GUKOVSKAYA · 1999 to 2026
$45.8M
USC RESEARCH CENTER FOR LIVER DISEASES: PILOT PROGRAMSP30DK048522 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KAPLOWITZ, NEIL · 1995 to 2020
$21.8M
NON-PARENCHYMAL LIVER CELL CORER24AA012885 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TSUKAMOTO, HIDEKAZU · 2001 to 2025
$8.1M
Immunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitorsU01AA027681 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI EL-KHOUEIRY, ANTHONY BOUTROS, KARIN, MICHAEL · 2018 to 2022
$3.6M
NANOG-positive cancer stem cells in liver oncogenesis induced by alcohol and HCVR01AA025204 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MACHIDA, KEIGO · 2017 to 2021
$1.9M
Nanog-positive cancer stem cells in and liver oncogenesis by alcohol and HCVR01AA018857 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MACHIDA, KEIGO · 2009 to 2013
$1.8M
LncRNA with MSI2 and super-enhancer in liver cancer stem cells induced by alcoholR21AA025470 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MACHIDA, KEIGO · 2018 to 2019
$444k
BLRD VA I01 BX001991BLRD VA IK6 BX004205NCI NIH HHS P30 CA014089NIAAA NIH HHS P50 AA011999NIAAA NIH HHS R01 AA018857NIAAA NIH HHS R01 AA025204NIAAA NIH HHS R21 AA025470NIAAA NIH HHS R24 AA012885NIAAA NIH HHS U01 AA027681NIDDK NIH HHS P30 DK048522
6 · The paper itself

Abstract

The synergistic effect of alcohol and HCV mediated through TLR4 signaling transactivates NANOG, a pluripotency transcription factor important for the stemness of tumor-initiating stem-like cells (TICs). NANOG together with the PRC2 complex suppresses expression of oxidative phosphorylation (OXPHOS) genes to generate TICs. The phosphodegron sequence PEST domain of NANOG binds EED to stabilize NANOG protein by blocking E3 ligase recruitment and proteasome-dependent degradation, while the tryptophan-rich domain of NANOG binds EZH2 and SUZ12. Human ARID1A gene loss results in the resistance to combined FAO and PRC2 inhibition therapies due to reduction of mitochondrial ROS levels. CRISPR-Cas9-mediated

Indexed as

Molecular physiologyStem cells research

Identifiers

PMID37448562
PMCPMC10336160
OpenAlexW4379744895

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.